Unmet clinical needs drive incumbents to keep innovating,
and our proprietary competitive-intelligence platform proactively surfaces white space

Who we monitor (21 parties · three market-access groups)

This list applies to both the Patent Monitoring System and the Intelligence Gathering System below — two views of the same set of parties: patent status and blocking vs. public FDA records.

The market is defined as the union of FDA (510(k) population) + CE-mark holders + NMPA China registrants. Key named rivals (the rest appear in the alert table and citation network below):

Patent Monitoring System

Automatically tracks patent status across Taiwan / US / EU / Japan: detects status changes, upcoming expiries, reinstatement windows and blocking events in real time. The figures below are synced from official patent databases; every record links back to the official page via "Verify".

Intelligence Gathering System

Major competitors' public records at the US FDA — MAUDE adverse events, recalls, 510(k) clearances, GUDID listings / delistings, establishment registrations & device listings, enforcement reports and warning letters — compared automatically each cycle.

Glossary

One-line explanations of the agencies and public-record terms appearing on this page.

Data-source agencies

FDA public-record terms

The above are term definitions based on each agency's public information; this page does not judge the cause of any individual recall, report or letter.